KLAYESTA Nystatin Topical Powder 100000 U/g Powder, 30 g — NDC 42806-186-30 (Billing 42806-0186-30)
This is a package of 30 g of KLAYESTA Nystatin Topical Powder 100000 U/g Powder from Epic Pharma, LLC, first listed with the FDA Apr 2023 and currently FDA-listed; retail pharmacies pay about $0.3056 per g (NADAC).
NDC database record
One package, one record: these facts belong to NDC 42806-186-30 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 42806 labeler · 186 product · 30 package
- Package marketed since
- Apr 14, 2023
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Billing quantity
- 30 g per package
- Barcode (UPC)
- 0342806186305, 0342806186152
- Medicaid fills, this package
- 16,026 prescriptions in the last four reported quarters
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 007284
- GCN: 30160
- GPI-14 (Medi-Span): 90150080002920
- HICL (First Databank): 004129
- AHFS class code: 08:14.28.00
- RxCUI (RxNorm): 646456
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 12, 2026
- FDA label on DailyMed · label index refreshed Nov 12, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 12, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 12, 2026
RxNorm drug class
This medicine belongs to the Polyene Antifungal class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Nov 12, 2026
Clinical
Topical nystatin is used to treat fungal infections of the skin. Nystatin is in a class of antifungal medications called polyenes. It works by stopping the growth of fungi that cause infection.
Read the full MedlinePlus article ↗- Nystatin treats Candida yeast infections. Depending on the form, that means the skin, the mouth, or the digestive tract lining. Make sure you use the form your prescriber chose for...
- You take it about four times a day. Put half the dose in each side of your mouth and keep it there as long as you can before swallowing. Keep going for at least 48 hours after symp...
- No. The skin products are not meant for oral, vaginal or eye use, or for infections throughout the body. Use them only on the skin as directed.
- Can I use Nystatin cream or powder in my mouth or eyes?
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 12, 2026
- FDA label on DailyMed · label index refreshed Nov 12, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per g | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.306 | $9.17 / 30 g |
| Medicaid paysCMS SDUD · 12 mo | $0.4781 | $14.34 / 30 g |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file · file of Nov 11, 2026
- CMS ASP pricing files · refreshed Oct 20, 2026
- CMS Medicaid State Drug Utilization Data · through Q1 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Marketing end | Status |
|---|---|---|---|---|---|---|
| 42806-0186-15 42806-186-15 | 15 g in 1 BOTTLE | $0.4018 / g | $6.03 | 2023-04-14 | — | Active |
| 42806-0186-30 You're viewing this | 30 g in 1 BOTTLE | $0.3056 / g | $9.17 | 2023-04-14 | — | Active |
| 42806-0186-60 42806-186-60 Main listing | 60 g in 1 BOTTLE | $0.2525 / g | $15.15 | 2023-04-14 | — | Active |
You're viewing one of 3 pack sizes for this product.
Per g, this pack runs about 21% above the cheapest pack (60 g, $0.2525 vs $0.3056 NADAC).
This pack accounts for about 20% of this product's recent Medicaid fills; most go to the 60 g pack. See all packs ↓
Pack size FAQ
What quantity is in this package?
How does this package differ from NDC 42806-0186-15?
What NDC number is used to bill for this package of KLAYESTA Nystatin Topical Powder 100000 U/g Powder?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Nystop 100000 [USP'U]/g 00574-2008-02 | Padagis | 60 g | $0.253 | AT | Availability likely | save 17% |
| Klayesta 100000 U/gthis 42806-0186-30 | Epic | 30 g | $0.306 | AT | Availability likely | — |
| Nystatin 100000 [USP'U]/g 75907-0060-30 | Dr. | 30 g | $0.306 | AT | Availability likely | — |
| Nystatin Topical Powder 100000 U/g 42806-0178-15 | Epic | 15 g | $0.307 | AT | FDA listed | +1% |
| Nyamyc 100000 [USP'U]/g 00832-0465-15 | Upsher-Smith | 1 bottle | $0.402 | AT | Availability likely | +32% |
| Nystatin 100000 [USP'U]/g 68382-0370-01 | Zydus | 15 g | $0.402 | AT | Availability likely | +32% |
| Nystatin 100000 [USP'U]/g 69315-0306-15 | Leading | 15 g | $0.402 | AT | Availability likely | +32% |
| Nystatin 100000 [USP'U]/g 72603-0491-01 | Northstar | 15 g | $0.402 | AT | Availability likely | +32% |
| Nystatin Topical Powder 100000 U/g 42806-0185-15 | Epic | 15 g | — | AT | FDA listed | — |
| Nystop 100000 [USP'U]/g 63629-8696-01 | Bryant | 15 g | — | AT | FDA listed | — |
| Nystop 100000 [USP'U]/g 63629-8697-01 | Bryant | 30 g | — | AT | FDA listed | — |
| Nystop 100000 [USP'U]/g 63629-8698-01 | Bryant | 60 g | — | AT | FDA listed | — |
| Nystatin 100000 [USP'U]/g 70771-1585-01 | Zydus | 15 g | — | AT | FDA listed | — |
| Nystop 100000 [USP'U]/g 71335-2845-01 | Bryant | 15 g | — | AT | FDA listed | — |
| Nystop 100000 [USP'U]/g 71335-2869-01 | Bryant | 30 g | — | AT | FDA listed | — |
| Nystop 100000 [USP'U]/g 72162-1124-02 | Bryant | 15 g | — | AT | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 12, 2026
- FDA Orange Book · refreshed Nov 6, 2026
- CMS NADAC weekly file · file of Nov 11, 2026
Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
- FDA Orange Book · refreshed Nov 6, 2026
What it looks like
Where does this data come from?
- FDA label on DailyMed · label index refreshed Nov 12, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Nystatin inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 24H4NWX5CO
Kaolin is a naturally occurring clay mineral. It's used in tablets and capsules as a filler and absorbent to add bulk, improve texture, and help bind ingredients together.
-
UNII 70097M6I30
Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
2 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Nov 12, 2026
- FDA openFDA NDC Directory · synced Nov 12, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Epic Pharma, LLC labeler code 42806
- AZITHROMYCIN 200 mg/5mL Powder, For Suspension NDC 42806-151-34
- Hydroxyzine Hydrochloride 10 mg Tablet, Film Coated NDC 42806-159-01
- Hydroxyzine Hydrochloride 25 mg Tablet, Film Coated NDC 42806-160-01
- Hydroxyzine Hydrochloride 50 mg Tablet, Film Coated NDC 42806-161-01
- Nystatin Topical Powder 100000 U/g Powder NDC 42806-178-15
- Nystatin Topical Powder 100000 U/g Powder NDC 42806-185-15
- Cholestyramine 4 g/9g Powder, For Suspension NDC 42806-265-98
- Cholestyramine 4 g/9g Powder, For Suspension NDC 42806-266-95
- Cholestyramine 4 g/9g Powder, For Suspension NDC 42806-267-93
- Cholestyramine Light 4 g/5.7g Powder, For Suspension NDC 42806-269-98
- Cholestyramine Light 4 g/5.7g Powder, For Suspension NDC 42806-270-95
- Cholestyramine Light 4 g/5.7g Powder, For Suspension NDC 42806-271-93
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 12, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE KLAYESTA is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species. KLAYESTA is not indicated for systemic, oral, intravaginal or ophthalmic use.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION Very moist lesions are best treated with the topical dusting powder. Adults and Pediatric Patients (Neonates and Older) Apply to candidal lesions two or three times daily until healing is complete. For fungal infection of the feet caused by Candida species, the powder should be dusted on the feet, as well as, in all foot wear.
⛔ Contraindications ▾
CONTRAINDICATIONS KLAYESTA is contraindicated in patients with a history of hypersensitivity to any of its components.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS The frequency of adverse events reported in patients using KLAYESTA is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application. (See PRECAUTIONS, General .)
🤰 Pregnancy ▾
Pregnancy Teratogenic Effects Animal reproduction studies have not been conducted with any KLAYESTA topical preparation. It also is not known whether these preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. KLAYESTA should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus.
🧒 Pediatric Use ▾
Pediatric Use Safety and effectiveness have been established in the pediatric population from birth to 16 years. (See DOSAGE AND ADMINISTRATION ).
🧓 Geriatric Use ▾
Geriatric Use Clinical studies with KLAYESTA did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Pharmacokinetics KLAYESTA is not absorbed from intact skin or mucous membrane. Microbiology Nystatin is an antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi, including Candida albicans, C. parapsilosis, C. tropicalis, C. guilliermondi, C. pseudotropicalis, C. krusei, Torulopsis glabrata, Tricophyton rubrum, T. mentagrophytes. Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components.
On repeated subculturing with increasing levels of nystatin, Candida albicans does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of Candida (C, tropicalis, C. guilliermondi, C. krusei, and C. stellatoides) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well.
This resistance is lost when the antibiotic is removed. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED KLAYESTA (nystatin topical powder, USP) is off-white to light yellow powder, and is supplied as 100,000 units nystatin per gram in plastic squeeze bottles. 15 g (NDC 42806-186-15) 30 g (NDC 42806-186-30) 60 g (NDC 42806-186-60)
📦 Storage and Handling ▾
STORAGE Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]; avoid excessive heat (40°C/104°F). Keep tightly closed. Distributed by: Epic Pharma, LLC Laurelton, NY 11413 Rev. 06-2025-00 MF186REV06/25 OS0017
📋 Description ▾
DESCRIPTION Nystatin is a polyene antifungal antibiotic obtained from Streptomyces noursei. The molecular formula for Nystatin is C 47 H 75 NO 17 . The molecular weight of Nystatin is 926.09. Structural formula: KLAYESTA is for dermatologic use. KLAYESTA contains 100,000 USP nystatin units per gram. Inactive ingredients: magnesium stearate and light kaolin. structural-formula.jpg
💬 Information for Patients ▾
Information for Patients Patients using this medication should receive the following information and instructions: 1. The patient should be instructed to use this medication as directed (including the replacement of missed doses). This medication is not for any disorder other than that for which it is prescribed.
2. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed. 3.
If symptoms of irritation develop, the patient should be advised to notify the physician promptly.
⚠️ Precautions ▾
PRECAUTIONS General KLAYESTA should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections. If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out infection caused by other pathogens.
Information for Patients Patients using this medication should receive the following information and instructions: 1. The patient should be instructed to use this medication as directed (including the replacement of missed doses). This medication is not for any disorder other than that for which it is prescribed.
2. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed. 3.
If symptoms of irritation develop, the patient should be advised to notify the physician promptly. Laboratory Tests If there is a lack of therapeutic response, KOH smears, cultures, or other diagnostic methods should be repeated. Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to evaluate the carcinogenic potential of KLAYESTA.
No studies have been performed to determine the mutagenicity of nystatin or its effects on male or female fertility. Pregnancy Teratogenic Effects Animal reproduction studies have not been conducted with any KLAYESTA topical preparation. It also is not known whether these preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity.
KLAYESTA should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus. Nursing Mothers It is not known whether KLAYESTA is excreted in human milk. Caution should be exercised when KLAYESTA is prescribed for a nursing woman.
Pediatric Use Safety and effectiveness have been established in the pediatric population from birth to 16 years. (See DOSAGE AND ADMINISTRATION ). Geriatric Use Clinical studies with KLAYESTA did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects.
Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
🍼 Nursing Mothers ▾
Nursing Mothers It is not known whether KLAYESTA is excreted in human milk. Caution should be exercised when KLAYESTA is prescribed for a nursing woman.
🧬 Pharmacokinetics ▾
Pharmacokinetics KLAYESTA is not absorbed from intact skin or mucous membrane.
🧬 Pharmacodynamics ▾
Microbiology Nystatin is an antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi, including Candida albicans, C. parapsilosis, C. tropicalis, C. guilliermondi, C. pseudotropicalis, C. krusei, Torulopsis glabrata, Tricophyton rubrum, T. mentagrophytes. Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components. On repeated subculturing with increasing levels of nystatin, Candida albicans does not develop resistance to nystatin.
Generally, resistance to nystatin does not develop during therapy. However, other species of Candida (C, tropicalis, C. guilliermondi, C. krusei, and C. stellatoides) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well. This resistance is lost when the antibiotic is removed.
Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to evaluate the carcinogenic potential of KLAYESTA. No studies have been performed to determine the mutagenicity of nystatin or its effects on male or female fertility.
📄 Package Label / Principal Display Panel ▾
PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 15 grams klayesta-15g
PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 30 grams klayesta-30g
PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 60 grams klayesta-60g